SARS-CoV-2感染增加急性胰腺炎严重程度及30天死亡率:COVID PAN协作研究
这项前瞻性国际多中心队列研究纳入2020年3月1日至7月23日期间1777例急性胰腺炎(AP)患者,其中149例(8.3%)合并SARS-CoV-2感染。结果显示,合并感染者更易发展为重症AP和ARDS,调整分析后住院时间延长、持续性器官衰竭和30天死亡率仍显著更高。
要点
- 合并SARS-CoV-2感染的AP患者重症率和30天死亡率显著升高。
- 调整混杂因素后,合并感染仍与住院时间延长、持续性器官衰竭和30天死亡率独立相关。
- 临床应早期识别AP患者的SARS-CoV-2感染状态以评估预后。
核心结论
- 合并SARS-CoV-2感染的急性胰腺炎患者发生重症AP、不良临床结局、住院时间延长和30天死亡率的风险增加。
研究设计与样本
- 前瞻性国际多中心队列研究,纳入2020年3月1日至7月23日期间连续入院的1777例急性胰腺炎患者,其中149例(8.3%)合并SARS-CoV-2感染,采用多水平logistic回归比较两组。
主要发现
- SARS-CoV-2阳性患者年龄更大、男性更多,更易发生重症AP和ARDS(p<0.001)。
- 未调整分析显示,SARS-CoV-2阳性患者ICU入住(OR 5.21,p<0.001)、局部并发症(OR 2.91,p<0.001)、持续性器官衰竭(OR 7.32,p<0.001)、住院时间延长(OR 1.89,p<0.001)和30天死亡率(OR 6.56,p<0.001)均更高。
- 调整分析显示,住院时间(OR 1.32,p<0.001)、持续性器官衰竭(OR 2.77,p<0.003)和30天死亡率(OR 2.41,p<0.04)在SARS-CoV-2合并感染组仍显著更高。
临床怎么用
- 对急性胰腺炎患者应评估SARS-CoV-2感染状态,合并感染者需警惕重症化、器官衰竭和死亡风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is emerging evidence that the pancreas may be a target organ of SARS-CoV-2 infection. This aim of this study was to investigate the outcome of patients with acute pancreatitis (AP) and coexistent SARS-CoV-2 infection. DESIGN: A prospective international multicentre cohort study including consecutive patients admitted with AP during the current pandemic was undertaken. Primary outcome measure was severity of AP. Secondary outcome measures were aetiology of AP, intensive care unit (ICU) admission, length of hospital stay, local complications, acute respiratory distress syndrome (ARDS), persistent organ failure and 30-day mortality. Multilevel logistic regression was used to compare the two groups. RESULTS: 1777 patients with AP were included during the study period from 1 March to 23 July 2020. 149 patients (8.3%) had concomitant SARS-CoV-2 infection. Overall, SARS-CoV-2-positive patients were older male patients and more likely to develop severe AP and ARDS (p<0.001). Unadjusted analysis showed that SARS-CoV-2-positive patients with AP were more likely to require ICU admission (OR 5.21, p<0.001), local complications (OR 2.91, p<0.001), persistent organ failure (OR 7.32, p<0.001), prolonged hospital stay (OR 1.89, p<0.001) and a higher 30-day mortality (OR 6.56, p<0.001). Adjusted analysis showed length of stay (OR 1.32, p<0.001), persistent organ failure (OR 2.77, p<0.003) and 30-day mortality (OR 2.41, p<0.04) were significantly higher in SARS-CoV-2 co-infection. CONCLUSION: Patients with AP and coexistent SARS-CoV-2 infection are at increased risk of severe AP, worse clinical outcomes, prolonged length of hospital stay and high 30-day mortality.
引用
- Pandanaboyana S, Moir J, Leeds JS, et al. SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study. Gut. 2021. PMID: 33547182. doi:10.1136/gutjnl-2020-323364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。